INTRODUCTION AND OBJECTIVES: Radical prostatectomy (RP) is a mainstay of treatment for men with clinically localized, high risk prostate cancer (CLHRPC). We assessed whether chemohormonal therapy with androgen deprivation therapy (ADT) plus docetaxel followed by RP would result in improved biochemical progression free survival (bPFS) than RP alone.
INTRODUCTION AND OBJECTIVES: Radical prostatectomy (RP) is a mainstay of treatment for men with clinically localized, high risk prostate cancer (CLHRPC). We assessed whether chemohormonal therapy with androgen deprivation therapy (ADT) plus docetaxel followed by RP would result in improved biochemical progression free survival (bPFS) than RP alone.
METHODS: CALGB 90203 (Alliance) is a Phase III study which randomly assigned in a 1:1 fashion men with CLHRPC (biopsy Gleason Grade Group 4 or 5 or Kattan pre-op nomogram bPFS < 60%) to RP alone or RP plus neoadjuvant ADT plus docetaxel (75 mg per square meter of body-surface area every 3 weeks for 6 cycles). The primary objective was to test the hypothesis that 3-year bPFS would be longer in the neoadjuvant chemohormonal therapy arm. Secondary endpoints included overall bPFS and overall survival (OS). The events for the bPFS endpoint are progression, defined as a serum PSA level > 0.2 ng/ml and rising on 2 separate occasions at least 3 months after RP, and death.
RESULTS: A total of 788 men (median age, 62; range: 32-83 years) were randomized. With a median follow-up of 5.1 years (range 0-11.2 years), no difference was seen in 3-year bPFS in men receiving neoadjuvant chemohormonal therapy and RP compared to RP alone (0.87 vs 0.82; p [ 0.13; Figure) . Expanding to the entire follow-up period, the bPFS rate was improved for the neoadjuvant arm (HR [ 0.66; 95%CI: 0.47-0.94; Figure) , however, the interpretation for the bPFS analyses was problematic due to 42% of patients not being evaluable for the primary endpoint because of receiving additional treatment prior to meeting the primary endpoint. An OS treatment evaluation provided evidence that patients randomized to neoadjuvant chemohormonal therapy and RP in this study had an improved OS rate relative to the RP-alone arm (HR [ 0.67; 95% CI: 0.43-1.06).
CONCLUSIONS: Neoadjuvant ADT plus docetaxel followed by RP did not increase 3-year bPFS compared to RP alone in men with CLHRPC. There was evidence that over time, bPFS and OS were improved in the men receiving neoadjuvant chemohormonal therapy and RP versus the men receiving RP alone. However, the 42% nonevaluable rate for bPFS tempers enthusiasm for the bPFS endpoint results.
Source of Funding: U10CA180821, U10CA180882, U10CA180863 (CCTG), U10CA180888 (SWOG), and SanofiAventis. ClinicalTrials.gov Identifier: NCT00430183.
LBA-13 IMPROVED DETECTION OF INDETERMINATE RENAL MASS VASCULARITY WITH SUPERB MICROVASCULAR IMAGING
Joon Yau Leong*, Corinne Wessner, Michael Kramer, Flemming Forsberg, Andrej Lyshchik, Edouard Trabulsi, Costas Lallas, John Eisenbrey, Philadelphia, PA INTRODUCTION AND OBJECTIVES: Vascular assessment of indeterminate renal masses (iRM) remains a crucial element of diagnostic imaging as the presence of blood flow within renal lesions suggests malignancy. Superb microvascular imaging (SMI) is a novel Doppler technique capable of detecting lower blood flow velocities. This study compared the utility of color and monochrome SMI (cSMI and mSMI) to color and power Doppler imaging (CD and PD) for the detection of microvasculature within iRM.
METHODS: Patients undergoing contrast-enhanced ultrasound (CEUS) evaluation for iRM from 10/9/2018-1/17/2019 provided informed consent to participate in this ongoing IRB approved study. CD, PD, cSMI and mSMI was performed prior to CEUS using an Aplio i800 with an i8CX1 transducer (Canon Medical Systems, Tustin, CA). For each lesion, a mean of 5 images were captured for each imaging mode. Following data acquisition, a total of 4 sets of images, each consisting of all images with a single modality, was randomized and read by a blinded sonographer. Each mode was assessed for the
